CoChat

Pegylated IL‐10 induces cancer immunity: The surprising role of IL‐10 as a potent inducer of IFN‐γ‐mediated CD8+ T cell cytotoxicity

Mumm, John B., Oft, Martin · 2013 · BioEssays

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Abstract

Recently, the development of several strategies based on immunotherapy has raised hopes for a more promising way to treat cancer patients. Here, we describe how interleukin (IL)‐10, a seemingly unlikely candidate, stimulates the immune system in a particularly efficacious way. IL‐10, an omnipotent anti‐inflammatory cytokine, delivers an equally potent immune stimulation in the context of CD8+ T cells and tumor immunity. By activation of tumor‐resident, tumor‐specific CD8+ T cells, pegylated IL‐10 can induce rejection of large and metastasizing tumors in mice. Here, we summarize the mechanisms of action of IL‐10, the reasons why the mechanisms may be crucial for the treatment of cancer patients, and the rationale for applying pegylated IL‐10 in the clinic.

Overview

Integrity signals

Registry

Crossref · 10.1002/bies.201300004

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 81 references

Cited by

Metadata

Authors
Mumm, J. B., & Oft, M.
Affiliations
ARMO Biosciences Redwood City CA USA
Corresponding author
Oft, Martin
Venue
BioEssays
Publisher
Wiley
Published
2013-05-13
Volume
35
Issue
7
Pages
623-631
ISSN
  • 0265-9247 (ISSN-L)
  • 1521-1878
OpenAlex
W2166586868
Cited by
53
References
81
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 4 · 2018: 5 · 2017: 5 · 2016: 1 · 2015: 8 · 2014: 2 · 2013: 1
FWCI
0.35
Type
journal article
Language
en
Open access
closed
Locations
  • BioEssays (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
IL-10, cancer immunotherapy, CD8+ T cells, antitumor immunity, tumor rejection, metastasis, anti-inflammatory cytokines, immunostimulation
MeSH terms
Animals, Disease Models, Animal, Humans, Immunotherapy, Interferon-gamma, Neoplasms, Polyethylene Glycols, Interleukin-10, CD8-Positive T-Lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.